Severe Cutaneous Adverse Reactions in Thailand

Last updated: February 15, 2019
Sponsor: Chulalongkorn University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Urticaria

White Cell Disorders

Rash

Treatment

N/A

Clinical Study ID

NCT02574988
Chula-ARC 001/15
  • Ages > 15
  • All Genders

Study Summary

The multicenter registry of patients with severe cutaneous adverse reactions among tertiary medical institutes in Thailand to study clinical characteristics, etiologies, therapeutic outcomes, quality of life, and the values of in vitro drug allergy diagnosis for the confirmation of the causative drugs

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients fulfilled criteria of probable or definite cases of SJS, TEN, DRESS, or AGEPaccording to RegiSCAR validation criteria as well as patients diagnosed with GBFDE

Exclusion

Exclusion Criteria:

  • Patients later confirmed to have other diagnosis than diseases mentioned above or haveno sufficient data for the registry

Study Design

Total Participants: 200
Study Start date:
January 01, 2014
Estimated Completion Date:
December 31, 2020

Study Description

Patients with severe cutaneous adverse reactions (Steven-Johnson Syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, and generalized bullous fixed drug eruption) among six tertiary medical institutes in Thailand will be recruited to study clinical characteristics, etiologies, therapeutic outcomes, quality of life, and the values of using laboratory techniques for the confirmation of the causative drugs

Connect with a study center

  • Faculty of Medicine, Chulalongkorn University

    Bangkok, 10330
    Thailand

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.